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Resveratrol, a polyphenol in red wine, has been re-
ported as a calorie restriction mimetic with potential
antiaging and antidiabetogenic properties. It is
widely consumed as a nutritional supplement, but
its mechanism of action remains a mystery. Here,
we report that the metabolic effects of resveratrol
result from competitive inhibition of cAMP-degrad-
ing phosphodiesterases, leading to elevated cAMP
levels. The resulting activation of Epac1, a cAMP
effector protein, increases intracellular Ca2+ levels
and activates the CamKKb-AMPK pathway via phos-
pholipase C and the ryanodine receptor Ca2+-release
channel. As a consequence, resveratrol increases
NAD+ and the activity of Sirt1. Inhibiting PDE4 with
rolipram reproduces all of the metabolic benefits of
resveratrol, including prevention of diet-induced
obesity and an increase in mitochondrial function,
physical stamina, and glucose tolerance in mice.
Therefore, administration of PDE4 inhibitors may
also protect against and ameliorate the symptoms
of metabolic diseases associated with aging.
INTRODUCTION
Calorie restriction (CR) is the most robust intervention demon-
strated to extend life span and delay the physiological deteriora-
tion associated with aging (McCay et al., 1935). Because CR
involves a number of overlapping and interconnected signaling
pathways, it is difficult to identify with certainty themechanism(s)underlying the beneficial effects of CR. Based on studies of the
budding yeast Saccharomyces cerevisiae, it was initially
proposed that CR extends life span via the activity of Sir2 (Lin
et al., 2000), the founding member of the conserved sirtuin family
of NAD+-dependent protein deacetylases (Guarente, 2006).
Although it remains unclear whether Sir2 plays a direct role in
the antiaging effects of CR (e.g., Kaeberlein et al., 2004), overex-
pression of Sirt1, the mammalian homolog of Sir2, has been re-
ported to protect mice from aging-related phenotypes that are
similar to type 2 diabetes (Banks et al., 2008; Bordone et al.,
2007; Pfluger et al., 2008), cancer (Herranz et al., 2010), and
Alzheimer’s disease (Donmez et al., 2010). Suggesting that
Sirt1 activity does not protect against aging-related diseases
by delaying the aging process, overexpression of Sirt1 does
not extend life span in mice (Herranz et al., 2010).
The positive health effects of CR and sirtuin activity in animal
models have provoked intense interest in the development of
small-molecule activators of Sirt1 to prevent or delay aging-
related diseases. An in vitro screen performed using a fluoro-
phore-tagged substrate identified resveratrol as an activator of
Sirt1 deacetylase activity (Howitz et al., 2003). Resveratrol is
a natural polyphenol produced by plants in response to environ-
mental stress (Signorelli and Ghidoni, 2005) and is present in
many plant-based foods, most notably red wine. Subsequent
work has shown that resveratrol extends the life spans of lower
eukaryotes (Gruber et al., 2007; Viswanathan et al., 2005;
Wood et al., 2004). These studies set the stage for testing resver-
atrol as a CR mimetic in mammals. In mice, long-term adminis-
tration of resveratrol induced gene expression patterns that
resembled those induced by CR and delayed aging-related
deterioration, even though it did not extend life span (Pearson
et al., 2008). Resveratrol protected against obesity and
development of insulin resistance in rodents fed a high-calorieCell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc. 421
diet (Baur et al., 2006; Lagouge et al., 2006). Resveratrol
also decreased insulin resistance in type 2 diabetic patients
(Brasnyo´ et al., 2011), suggesting that the pathway targeted by
resveratrol might be important for developing therapies for
type 2 diabetes.
An important mediator of the metabolic effects of resveratrol
(Lagouge et al., 2006; Um et al., 2010) is peroxisome prolifera-
tor-activated receptor g coactivator, PGC-1a (Puigserver et al.,
1998). It is a coactivator that controls mitochondrial biogenesis
and respiration and can contribute to fiber-type switching in
skeletal muscle (Lin et al., 2002) and increase adaptive thermo-
genesis in brown adipose tissue (Puigserver et al., 1998). Consis-
tent with the known ability of Sirt1 to deacetylate and activate
PGC-1a (Gerhart-Hines et al., 2007; Rodgers et al., 2005),
resveratrol increased Sirt1 and PGC-1a activity in mice fed a
high-fat diet (HFD) (Lagouge et al., 2006; Um et al., 2010).
Two findings have raised doubt that resveratrol is a direct Sirt1
activator. First, although resveratrol activates Sirt1 in vivo, it acti-
vates Sirt1 to deacetylate fluorophore-tagged substrates but
not native substrates in vitro (Beher et al., 2009; Borra et al.,
2005; Kaeberlein et al., 2005; Pacholec et al., 2010), suggesting
that resveratrol activates Sirt1 indirectly in vivo. Second, resver-
atrol activates AMP-activated protein kinase (AMPK) in vivo
(Baur et al., 2006; Canto´ et al., 2010; Dasgupta and Milbrandt,
2007; Park et al., 2007; Um et al., 2010). AMPK is a trimeric
complex that senses nutrient deprivation by sensing the AMP/
ATP (Carling et al., 1987) and ADP/ATP (Xiao et al., 2011) ratios.
AMPK, which is emerging as a key regulator of whole-body
metabolism, has been shown to increase NAD+ levels and acti-
vate Sirt1 and PGC-1a (Canto´ et al., 2009, 2010; Fulco et al.,
2008; Um et al., 2010). However, a causal link between the
increase in NAD+ and Sirt1 activation has not been established.
We and others have shown that AMPK-deficient mice are resis-
tant to the metabolic effects of resveratrol, providing evidence
that AMPK is a key mediator of the metabolic benefits produced
by resveratrol (Canto´ et al., 2010; Um et al., 2010). These findings
demonstrated that activation of Sirt1 and PGC-1a by resveratrol
is downstream of AMPK activation.
Studies on how resveratrol activates AMPK have led to
different and often conflicting mechanisms. Hawley et al. re-
ported that at a high concentration (100–300 mM), resveratrol
decreased ATP; and in a cell line expressing a mutated g
subunit of AMPK that made AMPK insensitive to AMP, resver-
atrol did not activate AMPK (Hawley et al., 2010). This sug-
gested that resveratrol, at high concentrations, activated
AMPK by decreasing energy and increasing the AMP/ATP or
ADP/ATP ratios. However, resveratrol can activate AMPK at
a concentration less than 10 mM (Dasgupta and Milbrandt,
2007; Feige et al., 2008; Park et al., 2007). At low concentra-
tions (%50 mM), resveratrol appears to activate AMPK without
decreasing energy (Dasgupta and Milbrandt, 2007; Suchan-
kova et al., 2009). As the plasma level after oral administration
of resveratrol is low (Crowell et al., 2004), the mechanism
by which resveratrol activates AMPK at physiologically rele-
vant concentrations most likely does not involve decreasing
energy.
For this report, we attempted to find the direct target of resver-
atrol and to elucidate the biochemical pathway by which it422 Cell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc.activates AMPK and produces metabolic benefits. We found
that resveratrol directly inhibits cAMP-specific phosphodiester-
ases (PDE) and identified the cAMP effector protein Epac1 as
a key mediator of the effects of resveratrol, which leads to the
activation of AMPK and Sirt1.
RESULTS
Resveratrol Activates AMPK in an
Epac1-Dependent Manner
A hint that cAMP may mediate the effects of resveratrol was
suggested by a previous study reporting that resveratrol
increased cAMP production in breast cancer cells (El-Mowafy
and Alkhalaf, 2003). In this study, we found that cAMP levels
increased significantly with a low dose (%50 mM) of resveratrol
in C2C12 myotubes (Figures 1A and 1B). To confirm that
resveratrol increased cAMP levels in vivo, we administered
resveratrol to mice by oral gavage and measured cAMP levels
in skeletal muscle and white adipose tissue (WAT) (Figure S1A
available online). We found that resveratrol increased cAMP
levels in both tissues. In contrast, resveratrol did not signifi-
cantly increase cGMP levels in myotubes (Figure S1B). The
possibility that the increase in cAMP production was respon-
sible for the activation of AMPK by resveratrol was examined
by treating myotubes and HeLa cells with resveratrol in the pres-
ence of the adenylyl cyclase (AC) inhibitor MDL-12,330A
(Figure 1C). In both cell types, MDL-12,330A prevented resvera-
trol (50 mM) from increasing the phosphorylation of both AMPK
(T172) and the AMPK substrate acetyl-CoA carboxylase (ACC)
(S79), which are markers of AMPK activity. These findings
indicate that cAMP signaling is essential for resveratrol to acti-
vate AMPK.
In most cells, intracellular cAMP signaling is mediated by two
groups of effectors that bind cAMP: protein kinase A (PKA) and
cAMP-regulated guanine nucleotide exchange factors (cAMP-
GEFs, Epac1 and Epac2) (de Rooij et al., 1998; Kawasaki
et al., 1998). To determine which of these two effector groups
activate AMPK in response to resveratrol, we treated cells with
siRNA specific for either the PKA catalytic subunit (PKAc) or
Epac1, which is more widely expressed than Epac2, prior to
resveratrol treatment. For this purpose, we used HeLa cells
instead of myotubes because Epac-regulated pathways affect
the myogenesis process (Pizon et al., 1999). As shown in Figures
1D and 1E, resveratrol increased the phosphorylation of AMPK
and ACC in the presence of PKA siRNA but not in the presence
of Epac1 siRNA, suggesting that Epac1 is essential for resvera-
trol to activate AMPK in HeLa cells.
Epac proteins function as GEFs for Rap1 and Rap2, members
of the Ras family of small G proteins that cycle between an
inactive GDP-bound state and an active GTP-bound state (de
Rooij et al., 1998; Kawasaki et al., 1998). Epac proteins catalyze
the exchange of GDP for GTP and thereby activate Rap1 and
Rap2. As a result, Epac activity increases the fraction of Rap
that is GTP bound, which can be detected by a pull-down assay
using the immobilized Ras association (RA) domain of RalGDS
(van Triest et al., 2001). We found that Rap1,GTP level in myo-
tubes is increased by resveratrol, indicating that resveratrol
increases Epac activity (Figure 1F). Treating myotubes with
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Figure 1. Resveratrol Activates AMPK in an Epac1-Dependent Manner
(A) Cyclic AMP levels in C2C12 myotubes 30 min after treatment with 0–100 mM resveratrol (Resv).
(B) Cyclic AMP levels in C2C12 myotubes after treatment with resveratrol (50 mM) for the indicated times.
(C) Phosphorylation of AMPK (T172) and AMPK substrate ACC (S79) after treatment with resveratrol (50 mM) in the presence of the AC inhibitor MDL-12,330A in
C2C12 myotubes and HeLa cells.
(D) The effect of PKA catalytic subunit a (PKAc) siRNA on resveratrol-induced phosphorylation of ACC and AMPK.
(E) The effect of Epac1 siRNA on resveratrol-induced phosphorylation of ACC and AMPK.
(F) GTP-bound Rap1 was pulled down using the immobilized ras-binding domain (RBD) of RalGDS (left). Quantification of binding is shown on the right (n = 3).
(G) Phosphorylation of ACC and AMPK induced by the Epac agonist 007 (10 mM).
See also Figure S1.the Epac-specific agonist 8-(4-chlorophenylthio)-2-O-methyla-
denosine-3,5-cAMP (also called 007) was sufficient to increase
the phosphorylation of AMPKandACC (Figure 1G). To determine
whether resveratrol directly activates Epac, we performed an
Epac activity assay in the presence of resveratrol. As shown in
Figures S1C and S1D, resveratrol had no direct effect on Epac
activity. Together, these findings indicate that resveratrol acti-
vates AMPK via Epac1, and resveratrol activates Epac1
indirectly.
Resveratrol Increases NAD+ Levels via Epac1
Because AMPK increases NAD+ levels and Sirt1 activity (Canto´
et al., 2009, 2010; Fulco et al., 2008; Um et al., 2010), the possi-bility that the resveratrol-mediated increase in NAD+ levels is
also Epac1 dependent was investigated. We found that the
resveratrol-mediated increase in NAD+ levels was prevented
by Epac1 siRNAbut not by control siRNA (Figure 2A). Sirt1-medi-
ated deacetylation of PGC-1a was then examined by immuno-
precipitation of PGC-1a and immunoblotting with antibody
specific for acetylated Lys. In the presence of Epac1 siRNA,
acetylation of PGC-1a was higher and did not decrease after
resveratrol treatment (Figure 2B), suggesting that resveratrol
activated Sirt1 in an Epac1-dependent manner. To examine
whether Epac activity is sufficient to induce mitochondrial
biogenesis, myotubes were treated with 007 for 3–4 days before
mitochondrial DNA (mtDNA) content wasmeasured. As shown inCell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc. 423
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Figure 2. Resveratrol Increases NAD+ Levels and Sirt1 Activity via Epac1
(A) NAD+, NADH, and NAD+/NADH ratio measured in cells treated with resveratrol and transfected with either control siRNA or Epac1 siRNA (n = 4).
(B) Deacetylation of PGC-1a induced by resveratrol in the presence of either control siRNA or Epac1 siRNA (left). Quantification of PGC-1a acetylation/total PGC-
1a is shown in the right panel (n = 3–4).
(C) mtDNA copy number in C2C12 myotubes after 3–4 days of treatment with 007 (10 mM) (n = 4).
(D) Oxygen consumption rate (OCR) in C2C12 myotubes 6 hr after treatment with 007 (10 mM, left), resveratrol (50 mM), rolipram (Rol, 25 mM), or vehicle
(Veh) (n = 3).
(E) Change in oxygen consumption rate (DOCR) in C2C12 with palmitoleate injection (100–400 mM) after 6 hr treatment with 007 (10 mM, left), resveratrol (50 mM),
rolipram (25 mM), or vehicle (n = 3).
(F) ROS levels in C2C12 myotubes treated with 007 (10 mM) for the indicated times (n = 4). Results are expressed as the mean ± SEM. *p < 0.05; **p < 0.01;
****p < 0.0001 compared to the negative control or vehicle-treated samples.Figure 2C, 007 increased mitochondrial content by almost 50%.
After only 6 hr, 007 significantly increased the basal oxygen
consumption rate of myotubes (Figure 2D, left). The measure-
ment of the oxygen consumption rate with increasing concen-
trations of palmitoleate demonstrated that 007 also increased
fat oxidation (Figure 2E, left). Consistent with resveratrol being
an Epac activator, resveratrol also increased the oxygen
consumption rate (Figure 2D, right) and fat oxidation (Figure 2E,
right). Resveratrol, despite increasing metabolic rate, has been
shown to reduce the production of reactive oxygen species
(ROS) (Um et al., 2010). We found that 007 also decreased
ROS levels (Figure 2F). Taken together, our findings provide
evidence that resveratrol activates Sirt1 indirectly in an Epac1-
dependent manner.
Resveratrol Activates the CamKKb-AMPK Pathway via
the PLC-Ryr2 Pathway
AMPK activation requires phosphorylation by one of two AMPK
kinases, LKB1 (Hawley et al., 2003; Woods et al., 2003) or
calcium/calmodulin-dependent kinase kinase b (CamKKb) (Haw-
ley et al., 2005; Hurley et al., 2005;Woods et al., 2005). Activation
of AMPK via energy depletion is thought to be dependent on
LKB1, and activation of AMPK via increased intracellular Ca2+
is dependent on CamKKb (Hawley et al., 2005; Hurley et al.,
2005; Woods et al., 2005). We asked whether resveratrol and
Epac1 activate the CamKKb-AMPK pathway, based on two
observations: First, resveratrol has been shown to increase424 Cell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc.cytosolic Ca2+ (Campos-Toimil et al., 2007; Sareen et al., 2007;
Vingtdeux et al., 2010). Second, in cardiac myocytes, Epac1
has been shown to increase cytosolic Ca2+ in a phospholipase
C (PLC)-dependent manner (Oestreich et al., 2007, 2009;
Schmidt et al., 2001) via calcium/calmodulin-dependent protein
kinase II (CamKII) (Pereira et al., 2007). To examine the potential
role of the CamKKb-AMPK pathway in resveratrol action, we
treated myotubes with either the Ca2+ chelator BAPTA-AM or
the CamKK inhibitor STO609. We found that both BAPTA-AM
(Figure 3A) andSTO609 (Figure 3B, left) decreased thephosphor-
ylation of AMPK and ACC after treatment with 50 mM resveratrol,
indicating that resveratrol stimulated the phosphorylation of
AMPK and ACC in a CamKKb-dependent manner. Because
high concentration of resveratrol was reported to activate
AMPK by decreasing energy (Hawley et al., 2010), we examined
whether the phosphorylation of AMPK and ACC by high concen-
tration of resveratrol (300 mM) was also sensitive to STO609. As
shown in Figure 3B (right), STO609 did not affect the phosphory-
lation of AMPK and ACC after treatment with 300 mM resveratrol,
indicating that the phosphorylation of AMPK and ACC by high
concentration of resveratrol did not require CaMKKb. To demon-
strate that the Epac-induced phosphorylation of AMPK and ACC
was also CamKKb dependent, we treated myotubes with 007 in
the presence of STO609 (Figure 3C). We found that STO609 pre-
vented 007 from inducing the phosphorylation of AMPK and
ACC. Together, these findings indicate that resveratrol at low
concentration activates the CamKKb-AMPK pathway via Epac1.
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Figure 3. PLC and Ryr Are Required for Resveratrol to Activate AMPK
(A) The phosphorylation of ACC and AMPK induced by resveratrol in C2C12 myotubes in the absence () or presence (+) of calcium chelator BAPTA-AM (20 mM).
We used myotubes derived from low-passage (<10) C2C12 cells.
(B) The phosphorylation of ACC and AMPK induced by resveratrol in C2C12myotubes in the absence () or presence (+) of the CamKK inhibitor STO609 (5 mg/ml)
for 50 mM (left) or 300 mM (right) resveratrol. We used myotubes derived from low-passage (<10) C2C12 cells.
(C) The phosphorylation of ACC and AMPK induced by 007 in C2C12 myotubes in the absence () or presence (+) of the CamKK inhibitor STO609 (5 mg/ml).
C2C12 cells of <10 passages were used.
(D) The increase in intracellular Ca2+ levels after resveratrol treatment (50 mM) in C2C12 myotubes loaded with Ca2+ indicator Fluo-4 AM in the presence of PLC
inhibitor U73122 (20 mM). F indicates the fluorescence level and DF indicates the change in fluorescence (n = 3).
(E) The phosphorylation of ACC and AMPK induced by resveratrol (50 mM) in C2C12 myotubes in the absence () or presence (+) of the PLC inhibitor U73122
(20 mM).
(F) Phosphorylation of ACC and AMPK induced by resveratrol in C2C12 myotubes in the absence () or presence (+) of the Ryr inhibitor ryanodine.
(G) Resveratrol-induced phosphorylation of S2815 in Ryr2 in the presence of siRNA specific for Epac1 or control siRNA.
See also Figure S2.As Epac1 increases intracellular Ca2+ via PLC, we examined
the role of PLC in resveratrol-induced Ca2+ release. The resver-
atrol-induced increase in intracellular Ca2+ was significantly
reduced in the presence of the PLC inhibitor U73122 (Figure 3D),
indicating that resveratrol increased intracellular Ca2+ in a PLC-
dependent manner. Consistent with this, U73122 prevented
resveratrol from stimulating the phosphorylation of AMPK and
ACC (Figure 3E). Upon activation of Epac, the ryanodine
receptor 2 (Ryr2) is phosphorylated and facilitates the release
of Ca2+ from the endoplasmic reticulum/sarcoplasmic reticulum
(ER/SR) (Wehrens et al., 2004). We treated myotubes with re-
sveratrol in the presence of the Ryr2 inhibitor ryanodine and
found that ryanodine prevented resveratrol from stimulating the
phosphorylation of AMPK and ACC (Figure 3F). Another ER/SR
Ca2+-release channel, the inositol triphosphate (IP3) receptor,
which is activated by IP3, does not appear to be involved in re-
sveratrol action because resveratrol was able to stimulate the
phosphorylation of AMPK and ACC in the presence of the IP3
receptor inhibitor 2-aminoethoxy-diphenyl borate (2-APB)
(Figure S2). We also used Epac1 siRNA to test the Epac1 depen-
dence of CamKII-mediated phosphorylation of Ryr2 residue
S2815 (Figure 3G). In agreement with our hypothesis, resveratrolcan only induce Ryr2 phosphorylation when Epac1 is active.
These findings indicate that resveratrol activates CamKK-
b-AMPK via the Epac1-PLC-Ryr pathway.
Resveratrol Is a Nonselective Phosphodiesterase
Inhibitor
The intracellular levels of cAMP are determined by the activities
of ACs, which synthesize cAMP from ATP, and cyclic nucleotide
PDEs, which hydrolyze cAMP or cGMP to AMP or GMP, respec-
tively. We measured the effect of resveratrol on the activities of
representatives of all three major subclasses of mammalian
ACs. As shown in Figure S3A, resveratrol had no effect on AC
activity, either in the basal state or in the activated state, suggest-
ing that resveratrol increases cAMP levels by inhibiting PDEs.
The PDE superfamily is comprised of 11 types of PDEs
(PDE1–11) of which multiple isoforms exist. PDEs have different
substrate specificities: PDEs 4, 7, and 8 are cAMP-selective
hydrolases, PDEs 5, 6, and 9 are cGMP-selective hydrolases,
and PDEs 1, 2, 3, 10, and 11 can hydrolyze both cAMP and
cGMP to varying degrees. Multiple members of the PDE super-
family are usually expressed in each cell. Wemeasured the activ-
ities of recombinant PDEs 1, 2, 3, 4, and 5 in the presenceCell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc. 425
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Figure 4. Resveratrol Is a PDE Inhibitor
(A) The effect of resveratrol on the activities of recombinant PDEs 1–5.
(B) Velocity of recombinant PDE3 activity as a function of cAMP and resveratrol concentration.
(C) Lineweaver-Burk plot of (B).
(D) Recombinant PDE3 was photoaffinity labeled with the fluorescent cAMP analog 8-azido-[DY-547]-cAMP in the presence of resveratrol or cAMP.
8-azido-[DY-547]-cAMP bound to PDE3 was visualized by fluorescence imaging (left). Quantification of 8-azido-[DY-547]-cAMP binding is shown in the right
panel (n = 3).of resveratrol. We found that resveratrol inhibited PDE1
(IC50 6 mM), PDE3 (IC50 10 mM), and PDE4 (IC50 14 mM)
but did not affect the activity of PDEs 2 or 5 (Figure 4A).
To determine how resveratrol inhibits PDEs, we measured the
effect of cAMP and resveratrol on the kinetics of recombinant
PDE3 activity (Figure 4B). At high concentrations of cAMP, the
inhibitory effect of resveratrol on PDE3 disappeared, suggesting
that resveratrol is competing with cAMP, and a Lineweaver-Burk
plot is consistent with a competitive inhibition mechanism (Fig-
ure 4C). To directly demonstrate that resveratrol competes
with cAMP in its binding site, we incubated PDE3 with the
fluorescent cAMP analog 8-azido[DY547]-cAMP, which cross-
links to its binding site when stimulated with UV, in the presence
of increasing concentrations of either resveratrol or cAMP. Both
resveratrol and cAMP competed with 8-azido[DY547]-cAMP for
the binding site in PDE3 (Figure 4D). Because the binding of
8-azido[DY547]-cAMP to PDE3 is irreversible, whereas the
binding of resveratrol or cAMP is reversible, the data shown in
Figure 4D are an underestimation of the actual competitiveness
of cAMP or resveratrol. A simulation of the docking of resveratrol
into the catalytic pocket of PDE3 suggests that resveratrol may
fit into the catalytic pocket in two orientations (Figures S3B–
S3E). Taken together, these findings support the conclusion
that resveratrol increases cAMP levels by competitively inhibit-
ing PDEs.426 Cell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc.Resveratrol Activates AMPK and Increases
Mitochondrial Biogenesis by Inhibiting PDEs
By treating myotubes with specific PDE3 and PDE4 inhibitors,
we determined that 76% of the total basal PDE activity was
attributable to PDE4 and 18% to PDE3 (Figures 5A and S4). To
corroborate our in vitro biochemical findings that resveratrol
inhibits PDEs, we sought genetic evidence by using a PDE4
mutation. Previously, it has been shown that the upstream
conserved regions (UCRs) of PDE4 increase the sensitivity of
PDE4 to competitive inhibitors, whereas the catalytic domain
of PDE4, which is missing the UCRs, is more resistant to the
known competitive inhibitors (Burgin et al., 2010). We found
that the UCRs of PDE4 are also important for inhibition by resver-
atrol because the resveratrol IC50 of the PDE4 catalytic domain
was approximately 2.4-fold higher than that of the full-length
PDE4 (33 mM versus 14 mM) (Figure 5B). If resveratrol
activates AMPK by inhibiting PDE4, resveratrol-induced phos-
phorylation of ACC and AMPK in myotubes expressing the
PDE4 catalytic domain should be reduced compared to those
expressing full-length PDE4. As shown in Figure 5C, this was
indeed the case.
If the metabolic effects of resveratrol result from inhibiting
PDEs, a known PDE inhibitor should produce metabolic effects
very similar to those produced by resveratrol. Because PDE4
makes up most of the PDE activity in myotubes, we treated
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Figure 5. Resveratrol Activates AMPK and Increases Mitochondrial Biogenesis by Inhibiting PDEs
(A) The relative contributions of PDE3 and PDE4 to the total PDE (t-PDE) activity in C2C12 myotube lysates were determined by adding either 1 mM cilostamide
(PDE3 inhibitor) or 10 mM rolipram (PDE4 inhibitor) to the PDE reaction (n = 3).
(B) The catalytic domain (Cat) of PDE4 is less sensitive to resveratrol than full-length (FL) PDE4. The resveratrol inhibitory curves of recombinant His-tagged PDE4
(FL, Cat) are shown.
(C) The phosphorylation of ACC and AMPK in C2C12 myotubes overexpressing either His-tagged PDE4-FL or PDE4-Cat after they were treated with resveratrol
(50 mM) for 3 hr. The levels of PDE4-FL and PDE4-Cat were detected with anti-His antibody.
(D) Cyclic AMP levels in C2C12 myotubes after treatment with rolipram (25 mM) for the indicated times.
(E) The phosphorylation of ACC and AMPK after treatment with rolipram (25 mM) in the presence of control siRNA (Contr) or Epac1 siRNA (Epac1).
(F) The phosphorylation of ACC and AMPK in skeletal muscle (gastrocnemius) after treatment with rolipram (2 mg/kg/day) for 14 weeks.
(G) NAD+, NADH, and the NAD+/NADH ratio in C2C12 myotubes were measured after 1–16 hr of rolipram treatment (25 mM).
(H) Deacetylation of PGC-1a in C2C12 myotubes treated with rolipram (left). Quantification of PGC-1a acetylation/total PGC-1a is shown in the right panel (n = 4).
(I) Expression levels (mRNA) of genes important for mitochondrial biogenesis and function as measured by real-time PCR from skeletal muscle of mice treated
with rolipram (n = 4).
(J) mtDNA content in C2C12 myotubes treated with cAMP (100 mM), resveratrol (50 mM), or rolipram (25 mM) for 4 days (n = 5).
(K) mtDNA content in skeletal muscle of mice fed resveratrol (400 mg/kg/day) or rolipram (2 mg/kg/day) for 14 weeks (n = 5).
(L) Mice fed rolipram for 12 weeks were exercised on a treadmill. Running distance prior to exhaustion is shown (n = 5).
Results are expressed as the mean ± SEM. *p < 0.05 and **p < 0.01 between the treatment groups.
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myotubes with the PDE4 inhibitor rolipram and found that roli-
pram increased cAMP to levels similar to those induced by re-
sveratrol in myotubes (Figure 5D). Like resveratrol, rolipram
stimulated the phosphorylation of AMPK and ACC in an
Epac1-dependent manner (Figure 5E). To demonstrate that roli-
pram can activate AMPK in vivo, we treated mice with rolipram
and harvested skeletal muscle. As shown in Figure 5F, roli-
pram-treated mice had higher levels of phosphorylated AMPK
and ACC than vehicle-treated mice. Like resveratrol, rolipram
increased NAD+ levels (Figure 5G) and increased PGC-1a de-
acetylation (Figure 5H), suggesting that rolipram increased
Sirt1 activity.
To test whether rolipram can reproduce the metabolic effects
of resveratrol in vivo, we determined the effect of rolipram (2 mg/
kg/day) on C57BL6/J mice fed with an HFD. After 12–14 weeks
of treatment, we isolated skeletal muscle and measured the
mRNA levels of genes that are known to be induced by resvera-
trol and AMPK, such as eNOS, PGC-1a, and others important for
mitochondrial biogenesis. We found that rolipram consistently
increased the mRNA levels of these genes (Figure 5I). In agree-
ment with this, treatment with resveratrol, rolipram, or cAMP
induced mitochondrial biogenesis in myotubes to comparable
levels (Figure 5J). Rolipram and resveratrol also increased mito-
chondrial content to similar levels in mouse skeletal muscle (Fig-
ure 5K). To determine whether increased mitochondrial function
improved exercise tolerance, we exercised rolipram-treated
mice on a treadmill. Rolipram-treated mice ran a significantly
greater distance on a treadmill before exhaustion than control
mice (445 ± 19m versus 268 ± 50m) (Figure 5L). Taken together,
these findings indicate that rolipram and resveratrol have very
similar effects on mitochondrial biogenesis in skeletal muscle.
PDE Inhibition Protects against Diet-Induced Obesity
and Glucose Intolerance
The similarity between the effects of rolipram and resveratrol
also extended to WAT. As was the case with resveratrol-treated
mice (Baur and Sinclair, 2006; Um et al., 2010), the phosphoryla-
tion levels of AMPK and ACC were increased in the WAT of
rolipram-treated mice (Figure 6A). C57BL6/J mice treated with
rolipram were resistant to weight gain on an HFD (Figure 6B)
and had less fat content (Figure 6C) even though their food intake
was similar to that of control mice (Figure 6D). Decreased weight
gain despite normal food intake suggests that rolipram increased
the metabolic rate. Because rolipram, like resveratrol and 007,
increased the oxygen consumption rate (Figure 2D, right) and
fat oxidation in myotubes (Figure 2E), we measured the oxygen
consumption rate in rolipram-treated mice. The oxygen
consumption rate was increased in rolipram-treated mice (Fig-
ure 6E), but physical activity levels were not affected (Figure 6F),
indicating that rolipram increased the basal metabolic rate.
Consistent with this, both resveratrol- and rolipram-treated
mice had higher body temperatures in the fasting state than
control mice (Figure 6G). Rolipram, like resveratrol (Um et al.,
2010), increased the expression levels of thermogenic genes
such as uncoupling proteins (UCPs) and PGC-1a in the adipose
tissue (Figure 6H).
PGC-1a increases ROS scavenging capacity (St-Pierre et al.,
2003). Consistent with rolipram-treated mice expressing higher428 Cell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc.levels of PGC-1a, rolipram-treated mice had lower ROS levels
(Figure 6I). Considering all of the metabolic changes that roli-
pram produced, including the reduction of ROS and fat mass
and increasedmitochondrial function, we expected that rolipram
would improve glucose tolerance. Indeed, rolipram-treated mice
were more glucose tolerant than were control mice (Figure 6J).
Glucagon-like peptide-1 (GLP-1), which is secreted from the
gut, has antidiabetogenic activities, and GLP-1 analogs, as
well as drugs that increase the endogenous GLP-1 levels, are
part of type 2 diabetes therapy. The expression of GLP-1 is posi-
tively regulated by cAMP (Gevrey et al., 2002) and therefore may
be induced when either resveratrol and rolipram inhibits PDEs.
Supporting this idea, we found that both resveratrol and rolipram
increased serum levels of GLP-1 by almost 20% (Figure 6K).
Together, these results indicate that both resveratrol and
rolipram may protect against type 2 diabetes by diverse mecha-
nisms including hormonal regulation.
DISCUSSION
By demonstrating that resveratrol activates the cAMP-Epac1-
AMPK-Sirt1 pathway, this study, in conjunction with previous
studies (Beher et al., 2009; Borra et al., 2005; Kaeberlein et al.,
2005; Pacholec et al., 2010), explains how resveratrol activates
Sirt1 without directly targeting it. Although resveratrol was
initially shown to directly activate Sirt1 in an assay that utilized
a fluorophore-linked substrate (Howitz et al., 2003), our studies
show that resveratrol indirectly activates Sirt1 in vivo due to its
effect on cAMP signaling.
Our findings on the mechanism of resveratrol action have
implications for other known putative Sirt1 activators such as
SRT1720, SRT2183, and SRT1460 (Milne et al., 2007; Pacholec
et al., 2010). Like resveratrol, they were discovered as Sirt1 acti-
vators by using the fluorophore-tagged substrate and only
exhibit Sirt1 activation in the presence of fluorophore-modified
substrate. Thus, it is likely that they may also activate Sirt1 via
an upstream target in vivo. Because the metabolic effects of
SRT1720 are nearly identical to those of resveratrol (Milne
et al., 2007; Feige et al., 2008), it is tempting to speculate that
these compounds, or at least SRT1720, act via pathways similar
to those of resveratrol.
cAMP signaling is highly complex, and its outcomes vary de-
pending on the effector activated by cAMP and on other factors
including the cell type, the cellular compartment of cAMP action,
and the duration and intensity of cAMP signaling. cAMP is a key
mediator of metabolic regulation, and the identification of PDEs
as resveratrol targets might explain how resveratrol mimics
some aspects of CR. Nutrient deprivation increases cAMP levels
as a consequence of increased glucagon and catecholamine
signaling and decreased insulin/IGF-1 signaling (Rondinone
et al., 2000; Selawry et al., 1973). Resveratrol, by increasing
cAMP levels and activating Epac1, may induce some of the path-
ways that are normally induced during CR (Figure 7). The positive
health benefits of PDE4 inhibitors, such as improved memory
(Burgin et al., 2010) and protection against aging-related
diseases such as Alzheimer’s (Smith et al., 2009) and Parkin-
son’s (Yang et al., 2008) diseases, have been demonstrated in
animal models. It is therefore possible that PDE4 inhibitors
p-ACC
p-AMPK
AMPK
ACC
Actin
Vehicle  Rolipram
A C 
E 
D B 
G F 
KH 
WAT
m
R
N
A 
le
ve
ls
 (A
.U
.) 
P
ho
sp
ho
ry
la
tio
n 
in
te
ns
ity
 
W
ei
gh
t g
ai
n 
(g
) 
Fa
t m
as
s 
in
de
x 
(g
/g
) 
Fo
od
 in
ta
ke
 (g
/d
) 
V
O
2 
(m
l/k
g/
h)
 
V
O
2 
(m
l/k
g/
h)
 
B
ea
m
 b
re
ak
s/
da
y 
C
or
e 
te
m
pe
ra
tu
re
 (o
 C
) 
R
O
S
 (%
) 
G
lu
co
se
 (m
g/
dl
) 
* 
* 
A
U
C
 (m
g/
dl
 
m
in
) 
* 
J
S
er
um
 G
LP
-1
 (p
M
) 
I 
Figure 6. PDE Inhibition Protects against Diet-Induced Obesity and Glucose Intolerance
(A) Rolipram increases the phosphorylation of ACC and AMPK inWAT. After 14 weeks of rolipram (2 mg/kg/day) treatment, epididymal fat was isolated frommice
and analyzed for AMPK and ACC phosphorylation. Quantification of phoshorylation intensity is shown on the right (n = 4).
(B) Rolipram protects against diet-induced obesity. Mice fed HFD were treated with either saline (vehicle) or rolipram (2 mg/kg/day) and the weight gain during
treatment is shown (n = 10 per group).
(C) The fat mass index (fat mass/total body weight) of mice from (B) was measured by NMR spectrometry (n = 10).
(D) HFD intake for vehicle- and rolipram-treated mice measured during weeks 1–4 of the treatment (n = 5).
(E) Twenty-four hour oxygen consumption (VO2) ofmice treatedwith either rolipramor vehicle for 12–14weeks. A 24 hr average of VO2 is shown on the right (n = 6).
(F) Rolipram does not affect locomotor activity. Twenty-four hour locomotor activity level was measured by beam-breaks (n = 5).
(G) Rolipram increases thermogenesis. The rectal temperatures of mice treated with either rolipram or vehicle in the fed or fasting (overnight) state (n = 7–10) are
shown.
(H) Rolipram increases the expression of genes important for thermogenesis in WAT. The transcriptional levels of PGC-1a, the uncoupling proteins, and eNOS in
WAT after 14 weeks of rolipram treatment were determined by real-time PCR (n = 5).
(I) ROS levels in WAT were measured by relative DCF fluorescence in WAT extract and shown as a percentage of that in control mice (n = 5).
(J) Glucose tolerance test (left) and the area under the curve (AUC) (right) are shown for HFD-fed mice treated with either rolipram or vehicle for 12–14 weeks
(n = 7–10).
(K) The serum levels of GLP-1 were measured in mice treated for 7 weeks with resveratrol or rolipram (n = 4–8).
Results are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 between treatment groups.may be useful for treating metabolic diseases and other aging-
related diseases in humans.
EXPERIMENTAL PROCEDURES
Cell Culture
C2C12 myoblast cells (ATCC) and HeLa cells were maintained in DMEM and
10% fetal bovine serum. To generate C2C12 myotubes, confluent culturesof C2C12 cells were grown in DMEM with 2% horse serum for 3–5 days. We
found that C2C12 myotubes generated from early passage (<10 passages
after purchase from ATCC) C2C12 myoblast cells yielded most consistent
results.PDE Assay
PDE activity was measured by modification of a previously published
method (Ahmad et al., 2009; Manganiello and Vaughan, 1973) by usingCell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc. 429
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Figure 7. Proposed Model of How Resveratrol Mimics CR
Resveratrol inhibits PDE activity and induces cAMP signaling via Epac1, which activates PLCε, resulting in Ca2+ release via the Ryr2 Ca2+ channel and, ultimately,
the activation of the CamKKb-AMPK pathway. CR increases cAMP levels by increasing glucagon and catecholamine levels, which activate AC activity and cAMP
production. AMPK increasesmitochondrial biogenesis and function by increasing PGC-1a expression, NAD+ levels, and Sirt1 activity. An additional pathway that
may contribute to resveratrol action is indicated with dotted lines.10 nM [3H]cAMP (45000 cpm) or [3H]cGMP as substrates. Less than
10%–15% of the substrates were hydrolyzed during the PDE reaction.
Portions of solubilized cell lysates were assayed for PDE activity by incuba-
tion with resveratrol (0–100 mM) or with specific PDE inhibitors. Recombi-
nant PDE1 (10 ng) activity was assayed by using 4 mg/ml calmodulin and
0.8 mM Ca2+ together with [3H]cAMP as substrate in the reaction mixture.
Recombinant PDE2 (15 ng) activity was assayed in the presence of 1 mM
cGMP, which activated it by 3 fold. Activities of recombinant PDE3
(1 ng) and PDE4 (1 ng) were assayed by incubation in a reaction mixture430 Cell 148, 421–433, February 3, 2012 ª2012 Elsevier Inc.containing 1 mg/ml BSA, with [3H]cAMP. Recombinant PDE5 (150 ng)
activity was assayed using [3H]cGMP as substrate. PDE activity is ex-
pressed as pmol of cAMP or cGMP hydrolyzed/min/mg protein. The
PDE3 inhibitor cilostamide and the PDE4 inhibitor rolipram were used to
define PDE specificity. Recombinant full-length PDE4D was purchased
from Signalchem, and the recombinant PDE4D catalytic domain was
purchased from Enzo Life Sciences. To measure the activities of PDE3 or
PDE4 in C2C12 lysates, PDE activity was measured in the presence of
1 mM cilostamide or 10 mM rolipram.
Animal Experiments
All experiments were approved by the NHLBI ACUC (Animal Care and Use
Committee). C57BL/6J mice were originally purchased from Jackson Labora-
tory. Four- to six-week-oldmalemicewere housedwith a 12 hr light-dark cycle
(light on 6 am–6 pm)with free access to food andwater. For all rolipram-related
studies, mice were dosed once daily by oral gavage with 2mg/kg/day rolipram
(Enzo Life Sciences) or with saline and were fed a HFD (40% calories from fat,
Research Diets) for up to 14 weeks. To measure the effect of resveratrol on
cAMP production, C57BL/6J mice were injected (intraperitoneally [i.p.]) with
resveratrol (20 mg/kg body weight) or with DMSO (vehicle). For studies
involving chronic resveratrol treatment, C57BL/6J mice were fed a HFD con-
taining resveratrol (400 mg/kg/day) for 14 weeks.
Metabolic Measurements
Body weight and caloric intake were monitored weekly. Plasma glucose was
measured by using a glucometer (Ascensia). For the glucose tolerance test,
mice were fasted for 16 hr, and 1mg/g glucose was injected i.p. Blood glucose
wasmeasured at 0, 15, 30, 45, 60, and 90min after injection. Prior to the tread-
mill endurance tests, the mice were trained for 3 days by running on an
Exer-3/6 mouse treadmill (Columbus Instruments) at 10 m/min for 5 min. For
the endurance test, the treadmill was set at a 15 incline, and the speed was
increased in a stepwise fashion (10 m/min for 10 min followed by 14 m/min
for 5 min and then the final speed of 18 m/min). The test was terminated
when mice reached exhaustion, which was defined as immobility for more
than 30 s. Locomotor activity of mice was measured by photobeam breaks
by using the Opto-Varimex-4 (Columbus Instruments). Indirect calorimetry
was performed using Oxymax chambers (Columbus Instruments). All mice
were acclimatized for 24 hr before measurements. Resting metabolic rate
was determined by calculating the average energy expenditure at each
30 min time point during a 24 hr period.
Statistical Analysis
Comparisons between the treatment groups were analyzed by two-tailed
Student’s t test, and comparisons involving repeated measurements were
analyzed by ANOVA repeatedmeasures. Results are expressed as themean ±
standard error of the mean (SEM). Significance was accepted at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at doi:10.1016/j.cell.
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